| NKG2D-CAR-transduced natural killer cells efficiently target multiple myeloma A Leivas, A Valeri, L Córdoba, A García-Ortiz, A Ortiz, L Sánchez-Vega, ... Blood Cancer Journal 11 (8), 146, 2021 | 102 | 2021 |
| Novel treatment strategy with autologous activated and expanded natural killer cells plus anti-myeloma drugs for multiple myeloma A Leivas, A Perez-Martinez, MJ Blanchard, E Martín-Clavero, ... Oncoimmunology 5 (12), e1250051, 2016 | 96 | 2016 |
| Visfatin impairs endothelium-dependent relaxation in rat and human mesenteric microvessels through nicotinamide phosphoribosyltransferase activity S Vallejo, T Romacho, J Angulo, LA Villalobos, E Cercas, A Leivas, ... PloS one 6 (11), e27299, 2011 | 92 | 2011 |
| Memory T cells expressing an NKG2D-CAR efficiently target osteosarcoma cells L Fernández, JY Metais, A Escudero, M Vela, J Valentín, I Vallcorba, ... Clinical Cancer Research 23 (19), 5824-5835, 2017 | 84 | 2017 |
| Haploidentical IL-15/41BBL activated and expanded natural killer cell infusion therapy after salvage chemotherapy in children with relapsed and refractory leukemia M Vela, D Corral, P Carrasco, L Fernández, J Valentín, B González, ... Cancer letters 422, 107-117, 2018 | 74 | 2018 |
| GMP-compliant manufacturing of NKG2D CAR memory T cells using CliniMACS prodigy L Fernández, A Fernández, I Mirones, A Escudero, L Cardoso, M Vela, ... Frontiers in Immunology 10, 2361, 2019 | 60 | 2019 |
| Overcoming tumor resistance mechanisms in CAR-NK cell therapy A Valeri, A García-Ortiz, E Castellano, L Córdoba, E Maroto-Martín, ... Frontiers in Immunology 13, 953849, 2022 | 46 | 2022 |
| MEK inhibition enhances the response to tyrosine kinase inhibitors in acute myeloid leukemia ML Morales, A Arenas, A Ortiz-Ruiz, A Leivas, I Rapado, ... Scientific reports 9 (1), 18630, 2019 | 32 | 2019 |
| NKG2D-CAR transduced primary natural killer cells efficiently target multiple myeloma cells A Leivas, P Rio, R Mateos, ML Paciello, A Garcia-Ortiz, L Fernandez, ... Blood 132, 590, 2018 | 24 | 2018 |
| Ps1209 Nkg2d and bcma-car Nk cells efficiently eliminate multiple myeloma cells. A comprehensive comparison between two clinically relevant cars E Maroto-Martín, J Encinas, A García-Ortiz, R Alonso, A Leivas, ... HemaSphere 3 (S1), 550-551, 2019 | 20 | 2019 |
| Visfatin/Nampt induces telomere damage and senescence in human endothelial cells LA Villalobos, A Uryga, T Romacho, A Leivas, CF Sánchez-Ferrer, ... International journal of cardiology 175 (3), 573-575, 2014 | 20 | 2014 |
| Optimizing the procedure to manufacture clinical-grade NK cells for adoptive immunotherapy A Fernández, A Navarro-Zapata, A Escudero, N Matamala, ... Cancers 13 (3), 577, 2021 | 19 | 2021 |
| How do we manufacture clinical‐grade interleukin‐15–stimulated natural killer cell products for cancer treatment? L Fernandez, A Leivas, J Valentin, A Escudero, D Corral, R de Paz, ... Transfusion 58 (6), 1340-1347, 2018 | 18 | 2018 |
| Multiple Infusions of Autologous Activated and Expanded Natural Killer Cells: A New Therapeutic Option for Multiple Myeloma A Leivas, A Pérez-Martínez, MJ Blanchard, EM Clavero, D Campana, ... Clinical Lymphoma, Myeloma and Leukemia 15, e297-e298, 2015 | 17 | 2015 |
| Autologous Activated and Expanded Natural Killer Cells Destroy Multiple Myeloma Clonogenic Tumor Cells through NKG2D and Its Ligands A Leivas, RM Risueño, A Pérez-Martínez, D Campana, JJ Lahuerta, ... Clinical Lymphoma, Myeloma and Leukemia 15, e245-e246, 2015 | 16 | 2015 |
| Autologous Activated and Expanded Natural Killer Cells Are Safe and Clinically Actives in Multiple Myeloma A Leivas, A Pérez-Martínez, MJ Blanchard, EM Clavero, D Campana, ... Blood 126 (23), 1856, 2015 | 15 | 2015 |
| High levels of cerebrospinal fluid kappa free light chains relate to IgM intrathecal synthesis and might have prognostic implications in relapsing multiple sclerosis J Castillo-Villalba, S Gil-Perotín, R Gasque-Rubio, L Cubas-Nuñez, ... Frontiers in immunology 13, 827738, 2022 | 13 | 2022 |
| Number and function of circulatory helper innate lymphoid cells are unaffected by immunosuppressive drugs used in solid organ recipients–a single centre cohort study E Gómez‐Massa, P Talayero, A Utrero‐Rico, R Laguna‐Goya, A Andrés, ... Transplant International 33 (4), 402-413, 2020 | 13 | 2020 |
| Efficacy of antiviral treatment in hepatitis C virus (HCV)-driven monoclonal gammopathies including myeloma A Rodríguez-García, M Linares, ML Morales, S Allain-Maillet, ... Frontiers in Immunology 12, 797209, 2022 | 12 | 2022 |
| Exploring NKG2D and BCMA-CAR NK-92 for adoptive cellular therapy to multiple myeloma EM Martín, J Encinas, A García-Ortiz, L Ugalde, RA Fernández, A Leivas, ... Clinical Lymphoma, Myeloma and Leukemia 19 (10), e24-e25, 2019 | 12 | 2019 |
